| Julie Christine Dueber, MD | |
|
800 Rose St # Ms 117, Lexington, KY 40536-0298 | |
| (859) 323-5425 | |
| Not Available |
| Full Name | Julie Christine Dueber |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 15 Years |
| Location | 800 Rose St # Ms 117, Lexington, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396988218 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 48178 (Kentucky) | Primary |
| 207ZC0500X | Pathology - Cytopathology | 48178 (Kentucky) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kentucky Hospital | Lexington, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kentucky Medical Services Foundation, Inc | 5698689909 | 806 |
News Archive
Exposure to goats could increase the risk of a certain type of lung cancer, according to French researchers.
Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.
Patients recovering from a right foot injury or surgery should think twice about how soon they want to begin driving again. According to a new study from the Journal of Bone and Joint Surgery (JBJS), it takes much longer to brake when the driver is wearing an immobilization device - like a splint or brace, than it does when wearing normal footwear.
Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.
Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.
› Verified 3 days ago
| Entity Name | Kentucky Medical Services Foundation, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326091448 PECOS PAC ID: 5698689909 Enrollment ID: O20031119000300 |
News Archive
Exposure to goats could increase the risk of a certain type of lung cancer, according to French researchers.
Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.
Patients recovering from a right foot injury or surgery should think twice about how soon they want to begin driving again. According to a new study from the Journal of Bone and Joint Surgery (JBJS), it takes much longer to brake when the driver is wearing an immobilization device - like a splint or brace, than it does when wearing normal footwear.
Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.
Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie Christine Dueber, MD 800 Rose St # Ms 117, Lexington, KY 40536-0298 Ph: (859) 323-5425 | Julie Christine Dueber, MD 800 Rose St # Ms 117, Lexington, KY 40536-0298 Ph: (859) 323-5425 |
News Archive
Exposure to goats could increase the risk of a certain type of lung cancer, according to French researchers.
Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.
Patients recovering from a right foot injury or surgery should think twice about how soon they want to begin driving again. According to a new study from the Journal of Bone and Joint Surgery (JBJS), it takes much longer to brake when the driver is wearing an immobilization device - like a splint or brace, than it does when wearing normal footwear.
Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.
Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.
› Verified 3 days ago
Dr. Kirk Phillip Heitman, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 800 Rose St, Ms117, Lexington, KY 40536 Phone: 859-257-1446 | |
Alexander Patrick Smith, Pathology Medicare: Medicare Enrolled Practice Location: 290 Big Run Rd, Lexington, KY 40503 Phone: 859-278-9513 | |
Dr. Amy Siegel Gewirtz, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 800 Rose St # Ms 117, Lexington, KY 40536 Phone: 859-323-5425 | |
Therese Jeanne Bocklage, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 800 Rose St # Ms 117, Lexington, KY 40536 Phone: 859-323-5425 | |
Dr. Paul Bachner, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 800 Rose Street, Lexington, KY 40536 Phone: 859-323-5425 | |
Dr. Peter Tobias Nelson, MD, PHD Pathology Medicare: Medicare Enrolled Practice Location: 800 Rose St # Ms 117, Lexington, KY 40536 Phone: 859-323-5425 | |
Dr. James L Bauer, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 290 Big Run Rd, Lexington, KY 40503 Phone: 859-278-9513 Fax: 859-277-6063 |